2440. Clinical outcomes in HIV+/HCV+ co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year single center experience.
Session: Poster Abstract Session: Viral Infections in Transplantation
Saturday, October 7, 2017
Room: Poster Hall CD

Clinical outcomes in HIV+/HCV+ co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year single center experience 

Background:

Previous studies have shown worse patient and graft survival following kidney transplant (KT) in HIV+/HCV+ co-infected patients compared to HIV+/HCV- recipients.  However, these studies were conducted prior to the advent of DAA therapy and data in the modern era is lacking.

Methods:

Single center retrospective study of HIV+/HCV+ co-infected patients who underwent deceased donor KT between 2007 and 2017.  All patients had ART-induced HIV viral load suppression at the time of transplant.

Results:

A total of 12 consecutive HIV+/HCV+ recipients were identified (table 1). Nine patients were HCV viremic at the time of transplant. Median time of follow up was 371 days. Six patients were transplanted in the DAA era (i.e., after 2013), 4 of them had HCV+ donors; all received DAA therapy, 5 of them post-transplant (median time from KT to DAA: 63 days; table 2). Patient and death censored graft survival at 9 months were 92% and 83% for the entire cohort, and 100% for the subgroup of patients transplanted in the DAA era - with no episodes of rejection nor infectious complications (table 3). 

Conclusion: Outcomes of HIV+/HCV+ KT recipients, including HCV+ to HCV+ transplants, in the DAA era were excellent in this cohort. Larger studies in this area are needed.   

Shweta Anjan, MD1, Jose F. Camargo, MD2, Michele I Morris, MD, FIDSA, FAST2, Lilian M. Abbo, MD3, Jacques Simkins, MD2, Gisele Guerra, MD4, Warren Kupin, MD4, Adela Mattiazzi, MD5, Linda Chen, MD6, George Burke, MD6, Jose Figueiro, MD6, Phillip Ruiz, MD7, Kalyan Bhamidimarri, MD8 and David Roth, MD5, (1)Infectious Disease, Jackson Memorial Hospital-University of Miami Miller School of Medicine, Miami, FL, (2)Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, (3)Infectious Disease, University of Miami-Jackson Health System, Miami, FL, (4)Medicine, University of Miami, Miami, FL, (5)University of Miami, Miami, FL, (6)University of Miami, Department of Surgery, Miami, FL, (7)Surgery and Pathology, University of Miami Miller School of Medicine, Miami, FL, (8)Hepatology, University of Miami, Miami, FL

Disclosures:

S. Anjan, None

J. F. Camargo, None

M. I. Morris, Novartis: Consultant , Consulting fee
Optimer: Investigator , Research support
Merck: Investigator , Research support
Chimerix: Investigator and Scientific Advisor , Consulting fee and Research support

L. M. Abbo, None

J. Simkins, None

G. Guerra, None

W. Kupin, None

A. Mattiazzi, None

L. Chen, None

G. Burke, None

J. Figueiro, None

P. Ruiz, None

K. Bhamidimarri, None

D. Roth, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.